• Grace Therapeutics priced a $10 million private placement of 4,761,904 common shares at USD 2.1 each.
• Deal expected to close Aug. 6, 2026, subject to customary conditions.
• Proceeds earmarked for manufacturing and regulatory work for GTx-104; cash runway expected to extend to end-2028.
• Shares sold in an unregistered transaction; resale registration statement to be filed with the SEC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608042100PRIMZONEFULLFEED9803955) on August 05, 2026, and is solely responsible for the information contained therein.